RxDoctor Payments Data

Dean le, MD

Neurology · Laguna Hills, CANPI 1982627089

Payments from drug & device makers

$23,785in general payments, 2019–2025

Across 955 payments — averaging $24.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • UCB, Inc.$2K
  • AstraZeneca$2K
  • Neurocrine Biosciences, Inc.$1K
  • EMD Serono, Inc.$1K
  • Biogen$1K
  • plus $13K from 54 others

What the payments were for

  • Speaking & faculty fees$230%
  • Food & beverage$23,51799%
  • Education$2441%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)129$2,565
UCB, Inc.74$2,246
AstraZeneca(2 entities)57$1,753
Neurocrine Biosciences, Inc.58$1,469
EMD Serono, Inc.39$1,467
Biogen59$1,307
SK Life Science, Inc.47$862
Lilly USA, LLC38$846
Eisai Inc.30$817
Lundbeck LLC37$682
Amgen(2 entities)23$627
Argenx US, Inc.19$559
Pfizer25$488
Novartis25$467
Amneal Pharmaceuticals LLC19$467
Johnson & Johnson(2 entities)13$433
Octapharma USA, Inc.9$421
Takeda Pharmaceuticals U.S.A., Inc.16$391
Grifols USA, LLC11$350
Teva Pharmaceuticals USA, Inc.20$345
Otsuka America Pharmaceutical, Inc.10$314
Bristol Myers Squibb9$311
Abbott9$285
ANI Pharmaceuticals, Inc.9$277
Harmony Biosciences LLC9$252
Genentech USA, Inc.6$231
Medtronic(2 entities)8$222
Sunovion Pharmaceuticals Inc.11$221
Livanova USA, Inc.11$213
Merz Pharmaceuticals, LLC6$184
MDD US Operations, LLC6$172
Impel Pharmaceuticals Inc.5$165
Adamas Pharmaceuticals, Inc.6$140
Axsome Therapeutics, Inc.5$140
CSL Behring6$138
Biohaven Pharmaceutical Holding Company Ltd.5$128
Boston Scientific7$126
Tanabe Pharma America, Inc.6$124
Avion Pharmaceuticals7$118
GE HealthCare5$117
Acadia Pharmaceuticals Inc4$97
Sanofi5$97
Corium, LLC4$86
Ipsen Biopharmaceuticals, Inc3$85
Averitas Pharma Inc.3$77
Upsher-smith Laboratories LLC3$73
Alnylam Pharmaceuticals Inc.3$71
Scilex Pharmaceuticals Inc.4$68
Supernus Pharmaceuticals, Inc.1$51
Vanda Pharmaceuticals Inc.2$50
Arbor Pharmaceuticals, Inc.3$47
Strongbridge US Inc.2$45
Neuropace, Inc.1$45
Kyowa Kirin, Inc.2$42
Revance Therapeutics, Inc.2$41
Biohaven Pharmaceuticals, Inc.2$38
Xeris Pharmaceuticals, Inc.2$35
Alfasigma USA, Inc.2$32
Assertio Therapeutics, Inc.2$32
Mallinckrodt Hospital Products Inc.1$27

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$23,785 in reported general payments places this provider in the 80th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$663,661
Medicare patients
527
Services billed
41,201

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GammaplexImmun Glob G(Igg)/Gly/Iga 0-5021$328,650
GammakedImmune Globul G/Gly/Iga Avg 4613$195,341
Gamunex-CImmune Globul G/Gly/Iga Avg 4622$165,506
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5012$105,381
BriviactBrivaracetam18$24,766
BrilintaTicagrelor33$22,441
Emgality PenGalcanezumab-Gnlm24$22,289
BotoxOnabotulinumtoxina17$21,976
Memantine Hcl631$19,581
RytaryCarbidopa/Levodopa32$17,386
UbrelvyUbrogepant11$16,966
Emgality SyringeGalcanezumab-Gnlm16$11,160
Aimovig AutoinjectorErenumab-Aooe15$10,684
Diclofenac Potassium13$6,211
Donepezil Hcl522$5,638

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Grifols USA, LLCGamunex-C$350$165,50622 claims
CSL BehringPrivigen$138$105,38112 claims
AbbVieBotox, Ubrelvy$2,565$38,94228 claims
UCB, Inc.Briviact$2,246$24,76618 claims
AstraZenecaBrilinta$1,753$22,44133 claims
Amneal Pharmaceuticals LLCRytary$467$17,38632 claims
PfizerEliquis$488$5,49512 claims
Upsher-smith Laboratories LLCTopiramate$73$2,555129 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,996 neurology providers in California.

Other neurology in Laguna Hills

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →